The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance. ⋯ At week 16, 67% of patients treated with mirikizumab 300 mg at 8-week intervals achieved PASI 90. The percentage of patients reporting at least one treatment-emergent adverse event was similar among patients treated with placebo or mirikizumab.